• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲胎蛋白(AFP)水平与肝癌患者病理分级、进展和生存的预后相关性。

The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma.

机构信息

Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou University, Yangzhou, 225001, China.

出版信息

Sci Rep. 2017 Oct 9;7(1):12870. doi: 10.1038/s41598-017-12834-1.

DOI:10.1038/s41598-017-12834-1
PMID:28993684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5634482/
Abstract

The purpose of this study was to conduct a comprehensive study of the clinical correlation between the alpha-fetoprotein (AFP) level at diagnosis and pathological grades, progression, and survival of patients with hepatocellular carcinoma (HCC). A total of 78,743 patients in Surveillance, Epidemiology, and End Results Program (SEER)-registered HCC was analyzed. The AFP test results for patients with HCC were mainly recorded as AFP-negative and AFP-positive. Logistic regression analysis revealed that the AFP level at diagnosis was an independent risk factor of pathological grade (odds ratio [OR], 2.559; 95% confidence interval [CI], 2.075-3.157; P < 0.001), TNM-7 stage (OR, 2.794; CI, 2.407-3.242; P < 0.001), and tumor size (OR, 1.748; 95% CI, 1.574-1.941; P < 0.001). Multivariable Cox regression analyses identified AFP level as an independent predictor of survival risk of patients with HCC who did not undergo surgery (hazard ratio [HR], 1.660; 95% CI, 1.534-1.797; P < 0.001), and those who underwent surgery (HR, 1.534; 95% CI, 1.348-1.745; P < 0.001). The AFP level at diagnosis was an independent risk predictor associated with pathological grade, progression, and survival. Further, surgery may not significantly reverse the adverse effects of AFP-positive compared with AFP-negative.

摘要

本研究旨在全面研究甲胎蛋白(AFP)水平与肝细胞癌(HCC)患者病理分级、进展和生存的临床相关性。分析了监测、流行病学和最终结果计划(SEER)登记的 HCC 患者共 78743 例。HCC 患者的 AFP 检测结果主要记录为 AFP 阴性和 AFP 阳性。Logistic 回归分析显示,诊断时 AFP 水平是病理分级(优势比[OR],2.559;95%置信区间[CI],2.075-3.157;P<0.001)、TNM-7 期(OR,2.794;CI,2.407-3.242;P<0.001)和肿瘤大小(OR,1.748;95%CI,1.574-1.941;P<0.001)的独立危险因素。多变量 Cox 回归分析确定 AFP 水平是未接受手术的 HCC 患者(危险比[HR],1.660;95%CI,1.534-1.797;P<0.001)和接受手术的 HCC 患者(HR,1.534;95%CI,1.348-1.745;P<0.001)生存风险的独立预测因素。诊断时 AFP 水平是与病理分级、进展和生存相关的独立危险因素。此外,手术可能不会显著逆转 AFP 阳性与 AFP 阴性相比的不利影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/5634482/a908e59aacf3/41598_2017_12834_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/5634482/5c5f500ce1ec/41598_2017_12834_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/5634482/a908e59aacf3/41598_2017_12834_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/5634482/5c5f500ce1ec/41598_2017_12834_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/5634482/a908e59aacf3/41598_2017_12834_Fig3_HTML.jpg

相似文献

1
The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma.甲胎蛋白(AFP)水平与肝癌患者病理分级、进展和生存的预后相关性。
Sci Rep. 2017 Oct 9;7(1):12870. doi: 10.1038/s41598-017-12834-1.
2
Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.根据基于监测、流行病学和最终结果(SEER)数据库的5年生存分析,将甲胎蛋白(AFP)纳入BCLC C期肝细胞癌的亚分类
Oncotarget. 2016 Dec 6;7(49):81389-81401. doi: 10.18632/oncotarget.13232.
3
Prognostic Significance of Preoperative Serum Alpha- fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.术前血清甲胎蛋白在肝细胞癌中的预后意义及其与临床病理因素的相关性:来自中国的单中心经验
Asian Pac J Cancer Prev. 2015;16(10):4421-7. doi: 10.7314/apjcp.2015.16.10.4421.
4
Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients.种族差异与甲胎蛋白检测和甲胎蛋白状态与肝细胞癌患者的诊断和预后相关。
Cancer Med. 2019 Nov;8(15):6614-6623. doi: 10.1002/cam4.2549. Epub 2019 Sep 13.
5
Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.治疗前白蛋白与 C 反应蛋白比值对肝癌患者的临床及预后意义。
BMC Cancer. 2019 Jun 4;19(1):538. doi: 10.1186/s12885-019-5747-5.
6
Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.腹水和甲胎蛋白可改善巴塞罗那临床肝癌分期的预后性能。
World J Gastroenterol. 2015 May 14;21(18):5654-62. doi: 10.3748/wjg.v21.i18.5654.
7
Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.经肝动脉化疗栓塞治疗后 AFP 状态对肝细胞癌结局的预后意义。
Ann Surg Oncol. 2012 Oct;19(11):3540-6. doi: 10.1245/s10434-012-2368-5. Epub 2012 Apr 25.
8
Edmondson-Steiner grade: A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio.埃德蒙森-施泰纳分级:无微血管侵犯的肝细胞癌复发和生存的关键预测指标。
Pathol Res Pract. 2017 Jul;213(7):824-830. doi: 10.1016/j.prp.2017.03.002. Epub 2017 Mar 8.
9
Distinctions between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive hepatocelluar carcinoma patients.甲胎蛋白阴性和阳性肝细胞癌患者的临床病理因素与预后的差异。
Asian Pac J Cancer Prev. 2012;13(2):559-62. doi: 10.7314/apjcp.2012.13.2.559.
10
Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.评估术前甲胎蛋白在乙型肝炎相关性肝细胞癌中的预后意义:正常并非新的正常。
Ann Surg Oncol. 2014 Mar;21(3):986-94. doi: 10.1245/s10434-013-3357-z.

引用本文的文献

1
Preliminary Evaluation of Plasma circ_0009910, circ_0027478, and miR-1236-3p as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.血浆circ_0009910、circ_0027478和miR-1236-3p作为肝细胞癌诊断和预后生物标志物的初步评估
Int J Mol Sci. 2025 May 19;26(10):4842. doi: 10.3390/ijms26104842.
2
Predicting postresection outcomes in solitary small hepatocellular carcinoma via pretreatment MR imaging features: subgroup analysis according to alpha-fetoprotein expression.通过术前磁共振成像特征预测孤立性小肝细胞癌切除术后的结局:根据甲胎蛋白表达进行亚组分析。
Eur Radiol. 2025 Apr 11. doi: 10.1007/s00330-025-11558-5.
3

本文引用的文献

1
Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma.甲胎蛋白(AFP):肝细胞癌中的一种多用途标志物。
Clin Chim Acta. 2016 Dec 1;463:39-44. doi: 10.1016/j.cca.2016.10.006. Epub 2016 Oct 11.
2
Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells.甲胎蛋白在促进肝癌细胞转移中起关键作用。
J Cell Mol Med. 2016 Mar;20(3):549-58. doi: 10.1111/jcmm.12745. Epub 2016 Jan 12.
3
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.
Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.
全身治疗联合肝动脉灌注化疗栓塞术与单纯全身治疗用于肝细胞癌的疗效比较:一项系统评价与荟萃分析
Int J Surg. 2025 May 1;111(5):3494-3507. doi: 10.1097/JS9.0000000000002326.
4
Knockdown of FANCI suppresses hepatocellular carcinoma development via the PI3K/Akt/GSK-3β pathway.敲低FANCI通过PI3K/Akt/GSK-3β信号通路抑制肝细胞癌的发展。
Heliyon. 2025 Feb 15;11(4):e42731. doi: 10.1016/j.heliyon.2025.e42731. eCollection 2025 Feb 28.
5
The impact of alpha-fetoprotein (AFP), child-turcotte-pugh (CTP) score and disease staging on the survival of hepatocellular carcinoma (HCC) patients: a retrospective cohort from single oncology center.甲胎蛋白(AFP)、Child-Turcotte-Pugh(CTP)评分及疾病分期对肝细胞癌(HCC)患者生存的影响:来自单一肿瘤中心的回顾性队列研究
Oncol Res. 2024 Dec 20;33(1):149-160. doi: 10.32604/or.2024.050903. eCollection 2025.
6
Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy.不可切除肝细胞癌患者接受三联联合治疗时早期甲胎蛋白和去γ羧基凝血酶原反应的预后意义
Front Immunol. 2024 Dec 12;15:1508028. doi: 10.3389/fimmu.2024.1508028. eCollection 2024.
7
Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances.肝细胞癌监测策略:主要指南与筛查进展
Cancers (Basel). 2024 Nov 24;16(23):3933. doi: 10.3390/cancers16233933.
8
Lenvatinib, sintilimab combined interventional treatment bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma.仑伐替尼、信迪利单抗联合介入治疗 贝伐珠单抗、信迪利单抗联合介入治疗中晚期不可切除肝细胞癌。
World J Gastroenterol. 2024 Nov 21;30(43):4620-4635. doi: 10.3748/wjg.v30.i43.4620.
9
The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local-regional therapy in unresectable hepatocellular carcinoma.预测不可切除肝细胞癌免疫治疗联合局部区域治疗预后的AFCRPLITY评分。
Ther Adv Med Oncol. 2024 Nov 19;16:17588359241297080. doi: 10.1177/17588359241297080. eCollection 2024.
10
Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma.乐伐替尼治疗晚期肝细胞癌患者的真实世界经验。
J Gastrointest Oncol. 2024 Oct 31;15(5):2216-2229. doi: 10.21037/jgo-24-351. Epub 2024 Sep 24.
肝细胞癌生物标志物临床应用的争议与展望
World J Gastroenterol. 2016 Jan 7;22(1):262-74. doi: 10.3748/wjg.v22.i1.262.
4
Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis.HBV 相关肝细胞癌伴或不伴肝硬化患者行肝切除术后的良好预后:一项长期随访分析。
J Gastroenterol. 2016 Jul;51(7):722-32. doi: 10.1007/s00535-015-1146-0. Epub 2015 Nov 25.
5
Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients.肝切除术后影响肝细胞癌复发及生存的因素:一项对601例中国患者的回顾性研究
Clin Transl Oncol. 2016 Aug;18(8):831-40. doi: 10.1007/s12094-015-1446-0. Epub 2015 Nov 17.
6
Clinical Impact of Anatomical Liver Resection for Hepatocellular Carcinoma with Pathologically Proven Portal Vein Invasion.经病理证实存在门静脉侵犯的肝细胞癌行解剖性肝切除的临床影响
World J Surg. 2016 Feb;40(2):402-11. doi: 10.1007/s00268-015-3231-1.
7
Prognostic Significance of Preoperative Serum Alpha- fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.术前血清甲胎蛋白在肝细胞癌中的预后意义及其与临床病理因素的相关性:来自中国的单中心经验
Asian Pac J Cancer Prev. 2015;16(10):4421-7. doi: 10.7314/apjcp.2015.16.10.4421.
8
Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.经动脉化疗栓塞治疗的肝细胞癌患者的预后因素。
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1114-23. eCollection 2014.
9
Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function?术前甲胎蛋白能否预测肝功能正常、无大血管侵犯的肝细胞癌患者肝切除术后的复发及死亡率?
Hepatol Res. 2014 Dec;44(14):E437-46. doi: 10.1111/hepr.12335. Epub 2014 May 6.
10
Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.评估术前甲胎蛋白在乙型肝炎相关性肝细胞癌中的预后意义:正常并非新的正常。
Ann Surg Oncol. 2014 Mar;21(3):986-94. doi: 10.1245/s10434-013-3357-z.